Sage Therapeutics faces challenges with a 90% value drop but shows promise with Zurzuvae for postpartum depression. Click ...

Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline. Read why SAGE ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...